The role of carrier size in the pharmacodynamics of antisense and siRNA oligonucleotides

Journal of Drug Targeting

Volumn 18, Issue 8, 2010, Pages 567-574

  Huang, Leaf ^a   Sullenger, Bruce ^b   Juliano, Rudy ^a  

^a University of North Carolina   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antisense; Biodistribution; Carrier; Delivery; Shape; SiRNA; Size

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APTAMER; DRUG CARRIER; LIPID; NANOCARRIER; NANOPARTICLE; SMALL INTERFERING RNA;

ARTICLE; BLOOD VESSEL PERMEABILITY; DRUG DELIVERY SYSTEM; GLOMERULUS FILTRATION; INFLAMMATION; LIVER; MACROMOLECULE; MOLECULE; PARTICLE SIZE; PRIORITY JOURNAL; SPLEEN; TUMOR; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; APTAMERS, NUCLEOTIDE; CAPILLARY PERMEABILITY; DRUG CARRIERS; ENDOTHELIAL CELLS; GLOMERULAR FILTRATION RATE; HUMANS; LIPOSOMES; NANOPARTICLES; OLIGONUCLEOTIDES, ANTISENSE; PARTICLE SIZE; RNA, SMALL INTERFERING;

EID: 77955214948     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611861003734019     Document Type: Article

References (73)

1. Agrawal S, Zhang R. (1997). Pharmacokinetics of oligonucleotides. Ciba Found Symp, 209, 60-75; discussion 75.
2. Akhtar S, Benter IF. (2007). Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest, 117, 3623-3632.
3. Amantana A, Moulton HM, Cate ML, Reddy MT, Whitehead T, HassingerJN, Youngblood DS, Iversen PL. (2007).Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide- morpholino oligomer conjugate. Bioconjug Chem, 18, 1325-1331.
4. Antohe F, Radulescu L, Gafencu A, Ghetie V Simionescu M. (2001). Expression of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. Hum Immunol, 62, 93-105.
5. Bonauer A, Carmona G, Iwasaki M, Mione M, Koyanagi M, Fischer A, Burchfield J, Fox H, Doebele C, Ohtani K, Chavakis E, Potente M, Tjwa M, Urbich C, Zeiher AM, Dimmeler S. (2009). MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science, 324, 1710-1713.
6. Braasch DA, Paroo Z, Constantinescu A, Ren G, Oz OK, Mason RP, Corey DR. (2004). Biodistribution of phosphodiester and phos- phorothioate siRNA. Bioorg Med Chem Lett, 14, 1139-1143.
7. Castanotto D, Rossi JJ. (2009). The promises and pitfalls of RNA- interference-based therapeutics. Nature, 457, 426-433.
8. Cesarone G, Edupuganti OP, Chen CP, Wickstrom E. (2007). Insulin receptor substrate 1 knockdown in human MCF7 ER+ breast cancer cells by nuclease-resistant IRS1 siRNA conjugated to a disulfide-bridged D-peptide analogue of insulin-like growth factor 1. Bioconjug Chem, 18, 1831-1840.
9. Champion JA, Katare YK, Mitragotri S. (2007). Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J Control Release, 121, 3-9.
10. Champion JA, Mitragotri S. (2009). Shape induced inhibition of phagocytosis of polymer particles. Pharm Res, 26, 244-249.
11. Christian DA, Cai S, Bowen DM, Kim Y, Pajerowski JD, Discher DE. (2009). Polymersome carriers: from self-assembly to siRNA and protein therapeutics. Eur J Pharm Biopharm, 71, 463-474.
12. Christian DA, Cai S, Garbuzenko OB, Harada T, Zajac AL, Minko T, Discher DE. (2009). Flexible filaments for in vivo imaging and delivery: persistent circulation of filomicelles opens the dosage window for sustained tumor shrinkage. Mol Pharm, 6, 1343-1352.
13. Chu TC, Twu KY, Ellington AD, Levy M. (2006). Aptamer mediated siRNA delivery. Nucleic Acids Res, 34, e73.
14. Crooke ST. (2004). Progress in antisense technology. Annu Rev Med, 55, 61-95.
15. Curnis F, Sacchi A, Corti A. (2002). Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J Clin Invest, 110, 475-482.
16. Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, Meyerholz DK, McCaffrey AP, McNamara JO 2nd, Giangrande PH. (2009). Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA- expressing tumors. Nat Biotechnol, 27, 839-849.
17. Decuzzi P, Pasqualini R, Arap W, Ferrari M. (2009). Intravascular delivery of particulate systems: does geometry really matter? Pharm Res, 26, 235-243.
18. Dos Santos N, Allen C, Doppen AM, Anantha M, Cox KA, Gallagher RC, Karlsson G, Edwards K, Kenner G, Samuels L, Webb MS, Bally MB. (2007). Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim Biophys Acta, 1768, 1367-1377.
19. Euliss LE, DuPont JA, Gratton S, DeSimone J. (2006). Imparting size, shape, and composition control of materials for nanomedicine. Chem Soc Rev, 35, 1095-1104.
20. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R. (2006). Targeted nanoparticle-aptamer bio- conjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA, 103, 6315-6320.
21. Fenske DB, MacLachlan I, Cullis PR. (2002). Stabilized plasmid-lipid particles: a systemic gene therapy vector. Meth Enzymol, 346, 36-71.
22. Fernandes MX, Ortega A, Lopez Martinez MC, Garcia de la Torre J. (2002). Calculation of hydrodynamic properties of small nucleic acids from their atomic structure. Nucleic Acids Res, 30, 1782-1788.
23. Fluiter K, ten Asbroek AL, de Wissel MB, Jakobs ME, Wissenbach M, Olsson H, Olsen O, Oerum H, Baas F. (2003). In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides. Nucleic Acids Res, 31, 953-962.
24. Fonseca SB, Pereira MP, Kelley SO. (2009). Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev, 61, 953-964.
25. Geary RS. (2009). Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol, 5, 381-391.
26. Geng Y, Dalhaimer P, Cai S, Tsai R, Tewari M, Minko T, Discher DE. (2007). Shape effects of filaments versus spherical particles in flow and drug delivery. Nat Nanotechnol, 2, 249-255. (Pubitemid 46739812)
27. Gratton SE, Ropp PA, Pohlhaus PD, Luft JC, Madden VJ, Napier ME, DeSimone JM. (2008). The effect of particle design on cellular internalization pathways. Proc Natl Acad Sci USA, 105, 11613-11618.
28. Greish K. (2007). Enhanced permeability and retention of macromo- lecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target, 15, 457-464.
29. Healy JM, Lewis SD, Kurz M, Boomer RM, Thompson KM, Wilson C, McCauley TG. (2004). Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm Res, 21, 2234-2246.
30. Heitz F, Morris MC, Divita G. (2009). Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol, 157, 195-206.
31. Hicke BJ, Stephens AW, Gould T, Chang YF, Lynott CK, Heil J, Borkowski S, Hilger CS, Cook G, Warren S, Schmidt PG. (2006). Tumor targeting by an aptamer. J Nucl Med, 47, 668-678.
32. Hoarau D, Delmas P, David S, Roux E, Leroux JC. (2004). Novel long- circulating lipid nanocapsules. Pharm Res, 21, 1783-1789.
33. Ivanova GD, Arzumanov A, Abes R, Yin H, Wood MJ, Lebleu B, Gait MJ. (2008). Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res, 36, 6418-6428.
34. Iyer AK, Khaled G, Fang J, Maeda H. (2006). Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today, 11, 812-818.
35. Jain RK. (1999). Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng, 1, 241-263.
36. Jang SH, Wientjes MG, Lu D, Au JL. (2003). Drug delivery and transport to solid tumors. Pharm Res, 20, 1337-1350.
37. Jearawiriyapaisarn N, Moulton HM, Buckley B, Roberts J, Sazani P, Fucharoen S, Iversen PL, Kole R. (2008). Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther, 16, 1624-1629.
38. Juliano R, Alam MR, Dixit V Kang H. (2008). Mechanisms and strategies for effective delivery of antisense and siRNA oligonucle- otides. Nucleic Acids Res, 36, 4158-4171.
39. Juliano RL. (2005). Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA. Curr Opin Mol Ther, 7, 132-136.
40. Kang H, Alam MR, Dixit V Fisher M, Juliano RL. (2008). Cellular delivery and biological activity of antisense oligonucleotides conjugated to a targeted protein carrier. Bioconjug Chem, 19, 2182-2188.
41. Klibanov AL, Maruyama K, Torchilin VP, Huang L. (1990). Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett, 268, 235-237.
42. Kong G, Braun RD, Dewhirst MW. (2000). Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res, 60, 4440-4445.
43. Kumar P, Shen Q, Pivetti CD, Lee ES, Wu MH, Yuan SY. (2009). Molecular mechanisms of endothelial hyperpermeability: implications in inflammation. Expert Rev Mol Med, 11, e19.
44. Lebleu B, Moulton HM, Abes R, Ivanova GD, Abes S, Stein DA, Iversen PL, Arzumanov AA, Gait MJ. (2008). Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev, 60, 517-529.
45. Li SD, Chen YC, Hackett MJ, Huang L. (2008). Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther, 16, 163-169.
46. Li SD, Chono S, Huang L. (2008a). Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J Control Release, 126, 77-84.
47. Li SD, Chono S, Huang L. (2008b). Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther, 16, 942-946.
48. Liu D, Mori A, Huang L. (1992). Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1- containing liposomes. Biochim Biophys Acta, 1104, 95-101.
49. Marsolais D, Rosen H. (2009). Chemical modulators of sphingosine- 1-phosphate receptors as barrier-oriented therapeutic molecules. Nat Rev Drug Discov, 8, 297-307.
50. McNamara JO 2nd, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, Sullenger BA, Giangrande PH. (2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol, 24, 1005-1015.
51. Mi J, Liu Y, Rabbani ZN, Yang Z, Urban JH, Sullenger BA, Clary BM. (2010). In vivo selection of tumor-targeting RNA motifs. Nat Chem Biol, 6, 22-24.
52. Minshall RD, Malik AB. (2006). Transport across the endothelium: regulation of endothelial permeability. Handb Exp Pharmacol, 176, 107-144.
53. Moreira JN, Gaspar R, Allen TM. (2001). Targeting Stealth liposomes in a murine model of human small cell lung cancer. Biochim Biophys Acta, 1515, 167-176.
54. Muro S, Garnacho C, Champion JA, Leferovich J, Gajewski C, Schuchman EH, Mitragotri S, Muzykantov VR. (2008). Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. Mol Ther, 16, 1450-1458.
55. Nimjee SM, Rusconi CP, Sullenger BA. (2005). Aptamers: an emerging class of therapeutics. Annu Rev Med, 56, 555-583.
56. Noguchi Y, Wu J, Duncan R, Strohalm J, Ulbrich K, Akaike T, Maeda H. (1998). Early phase tumor accumulation of macromol- ecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res, 89, 307-314.
57. Opanasopit P, Nishikawa M, Hashida M. (2002). Factors affecting drug and gene delivery: effects of interaction with blood components. Crit Rev Ther Drug Carrier Syst, 19, 191-233.
58. Pieve CD, Perkins AC, Missailidis S. (2009). Anti-MUC1 aptamers: radi- olabelling with (99m)Tc and biodistribution in MCF-7 tumour- bearing mice. Nucl Med Biol, 36, 703-710.
59. Que-Gewirth NS, Sullenger BA. (2007). Gene therapy progress and prospects: RNA aptamers. Gene Ther, 14, 283-291.
60. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. (2004). Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J, 377, 159-169.
61. Rippe B, Rosengren BI, Carlsson O, Venturoli D. (2002). Transendothelial transport: the vesicle controversy. J Vasc Res, 39, 375-390.
62. Roberts J, Palma E, Sazani P, 0rum H, Cho M, Kole R. (2006). Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol Ther, 14, 471-475.
63. Roopenian DC, Akilesh S. (2007). FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol, 7, 715-725.
64. Sazani P, Kole R. (2003). Therapeutic potential of antisense oligonu- cleotides as modulators of alternative splicing. J Clin Invest, 112, 481-486.
65. Scherphof GL. (1991) In vivo behavior of liposomes: Interactions with the mononuclear phagocyte system and implications for drug targeting. Targeted Drug Delivery, R.L. Juliano (ed.) Springer, Berlin, New York.
66. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M, Kesavan V Lavine G, Pandey RK, Racie T, Rajeev KG, Rohl I, Toudjarska I, Wang G, Wuschko S, Bumcrot D, Koteliansky V Limmer S, Manoharan M, Vornlocher HP. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 432, 173-178.
67. Sullenger BA, Cech TR. (1993). Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science, 262, 1566-1569.
68. van de Water FM, Boerman OC, Wouterse AC, Peters JG, Russel FG, Masereeuw R. (2006). Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos, 34, 1393-1397.
69. Watson SR, Chang YF, O'Connell D, Weigand L, Ringquist S, Parma DH. (2000). Anti-L-selectin aptamers: binding characteristics, phar- macokinetic parameters, and activity against an intravascular target in vivo. Antisense Nucleic Acid Drug Dev, 10, 63-75.
70. Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, Rajeev KG, Nakayama T, Charrise K, Ndungo EM, Zimmermann T, Koteliansky V Manoharan M, Stoffel M. (2007). Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol, 25, 1149-1157.
71. Yu RZ, Geary RS, Monteith DK, Matson J, Truong L, Fitchett J, Levin AA. (2004). Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys. J Pharm Sci, 93, 48-59.
72. Zhou J, Li H, Li S, Zaia J, Rossi JJ. (2008). Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther, 16, 1481-1489.
73. Zhou J, Rossi JJ. (2009). The therapeutic potential of cell-internalizing aptamers. Curr Top Med Chem, 9, 1144-1157.